333 related articles for article (PubMed ID: 12393605)
21. High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission.
Stein AS; O'Donnell MR; Slovak ML; Nademanee A; Dagis A; Schmidt GM; Parker PM; Snyder DS; Smith EP; Somlo G; Margolin KA; Arber D; Niland J; Forman SJ
Leukemia; 2000 Jul; 14(7):1191-6. PubMed ID: 10914541
[TBL] [Abstract][Full Text] [Related]
22. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
23. Proportion of blasts with a clear halo around nucleoli at the end of induction therapy of acute myeloid leukemia correlates with achievement of complete remission, remission duration and relapse.
Emura I; Chou T; Ishiguro T; Kakihara T; Naito M; Yoshizawa H; Arakawa M
Pathol Int; 1998 Jul; 48(7):526-35. PubMed ID: 9701015
[TBL] [Abstract][Full Text] [Related]
24. [A new prognostic stratification for patients with acute myeloid leukemia].
Jiang B; Mi YC; Lin D; Cai XJ; Fu MW; Li W; Wang Y; Liu XP; Xue YP; Bian SG; Wang JX
Zhonghua Nei Ke Za Zhi; 2009 Apr; 48(4):316-20. PubMed ID: 19576124
[TBL] [Abstract][Full Text] [Related]
25. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
26. Remission induction therapy: the more intensive the better?
Büchner T; Hiddemann W; Berdel W; Wörmann B; Löffler H; Schoch C; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Andreesen R; Balleisen L; Haase D; Eimermacher H; Aul C; Rasche H; Uhlig J; Grüneisen A; Reis HE; Hartlapp J; Hirschmann WD; Weh HJ; Pielken HJ; Gassmann W; Sauerland MC; Heinecke A
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S41-4. PubMed ID: 11587366
[TBL] [Abstract][Full Text] [Related]
27. Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.
Lengfelder E; Hanfstein B; Haferlach C; Braess J; Krug U; Spiekermann K; Haferlach T; Kreuzer KA; Serve H; Horst HA; Schnittger S; Aul C; Schultheis B; Erben P; Schneider S; Müller-Tidow C; Wörmann B; Berdel WE; Sauerland C; Heinecke A; Hehlmann R; Hofmann WK; Hiddemann W; Büchner T;
Ann Hematol; 2013 Jan; 92(1):41-52. PubMed ID: 23090499
[TBL] [Abstract][Full Text] [Related]
28. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
Byrd JC; Mrózek K; Dodge RK; Carroll AJ; Edwards CG; Arthur DC; Pettenati MJ; Patil SR; Rao KW; Watson MS; Koduru PR; Moore JO; Stone RM; Mayer RJ; Feldman EJ; Davey FR; Schiffer CA; Larson RA; Bloomfield CD;
Blood; 2002 Dec; 100(13):4325-36. PubMed ID: 12393746
[TBL] [Abstract][Full Text] [Related]
29. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
Creutzig U; Büchner T; Sauerland MC; Zimmermann M; Reinhardt D; Döhner H; Schlenk RF
Cancer; 2008 Feb; 112(3):562-71. PubMed ID: 18076087
[TBL] [Abstract][Full Text] [Related]
30. [Outcomes of adult patients with
Ren X; Zhao T; Wang J; Zhu HH; Jiang H; Jia JS; Yang SM; Jiang B; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2018 Jan; 39(1):15-21. PubMed ID: 29551027
[No Abstract] [Full Text] [Related]
31. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities.
Kern W; Schoch C; Haferlach T; Braess J; Unterhalt M; Wörmann B; Büchner T; Hiddemann W
Leukemia; 2000 Feb; 14(2):226-31. PubMed ID: 10673737
[TBL] [Abstract][Full Text] [Related]
32. The percentage of peripheral blood blasts on day 7 of induction chemotherapy predicts response to therapy and survival in patients with acute myeloid leukemia.
Gao S; Tan Y; Liu X; Su L; Yu P; Han W; Cui J; Li W
Chin Med J (Engl); 2014; 127(2):290-3. PubMed ID: 24438618
[TBL] [Abstract][Full Text] [Related]
33. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy.
Short NJ; Benton CB; Chen HC; Qiu P; Gu L; Pierce S; Brandt M; Maiti A; Min TL; Naqvi K; Quintas-Cardama A; Konopleva M; Kadia T; Cortes J; Garcia-Manero G; Ravandi F; Jabbour E; Kantarjian H; Andreeff M
Am J Hematol; 2016 Dec; 91(12):1221-1226. PubMed ID: 27474808
[TBL] [Abstract][Full Text] [Related]
34. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
[TBL] [Abstract][Full Text] [Related]
35. [Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Qin T; Xu Z; Zhang Y; Lin Y; Ru K; Fang L; Zhang H; Pan L; Hu N; Qu S; Wang J; Xing R; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):94-9. PubMed ID: 27014976
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.
List AF; Spier CS; Grogan TM; Johnson C; Roe DJ; Greer JP; Wolff SN; Broxterman HJ; Scheffer GL; Scheper RJ; Dalton WS
Blood; 1996 Mar; 87(6):2464-9. PubMed ID: 8630412
[TBL] [Abstract][Full Text] [Related]
37. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
Ravandi F; Jorgensen J; Borthakur G; Jabbour E; Kadia T; Pierce S; Brandt M; Wang S; Konoplev S; Wang X; Huang X; Daver N; DiNardo C; Andreeff M; Konopleva M; Estrov Z; Garcia-Manero G; Cortes J; Kantarjian H
Cancer; 2017 Feb; 123(3):426-435. PubMed ID: 27657543
[TBL] [Abstract][Full Text] [Related]
38. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.
Leith CP; Kopecky KJ; Godwin J; McConnell T; Slovak ML; Chen IM; Head DR; Appelbaum FR; Willman CL
Blood; 1997 May; 89(9):3323-9. PubMed ID: 9129038
[TBL] [Abstract][Full Text] [Related]
39. Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
Maurillo L; Buccisano F; Spagnoli A; Del Poeta G; Panetta P; Neri B; Del Principe MI; Mazzone C; Consalvo MI; Tamburini A; Ottaviani L; Fraboni D; Sarlo C; De Fabritiis P; Amadori S; Venditti A
Haematologica; 2007 May; 92(5):605-11. PubMed ID: 17488683
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]